ImmuCell to Hold Virtual-Only Annual Meeting of Stockholders
June 04 2024 - 4:05PM
ImmuCell Corporation (Nasdaq: ICCC)
(“ImmuCell” or the “Company”), a growing animal health company that
develops, manufactures and markets scientifically proven and
practical products that improve the health and productivity of
dairy and beef cattle, today announced that its 2024 Annual
Meeting of Stockholders (the “Annual Meeting”) will be conducted
virtually on Thursday, June 13, 2024, at 9:30 AM ET, as previously
disclosed in its Proxy Statement filed with the Securities and
Exchange Commission (“SEC”) on April 26, 2024.
The Annual Meeting will be held by remote
communication in the form of a telephone conference call and a live
audio webcast, rather than as an in-person event. Stockholders of
record of the Company’s common stock at the close of business on
April 15, 2024, are invited to participate in the Annual Meeting by
dialing (844) 855-9502 toll free or (412) 317-5499 for
international access or by accessing the live audio webcast at
https://app.webinar.net/znQpX7rqZLm. Participation via the live
audio webcast will be in listen-only mode. Participation in the
informal Q&A session, which will take place after the formal
business of the meeting is concluded, will be limited to the
telephone conference call connection.
A meeting replay will be available for seven days after the
meeting by dialing (877) 344-7529 toll free or (412) 317-0088 for
international access, using replay access code: 7085899 until June
19, 2024.
Stockholders, regardless of their plans to attend the
virtual-only meeting, are encouraged to vote and submit their
proxies in advance of the Annual Meeting using one of the methods
described in the proxy materials. Stockholders may continue to use
the voting instruction form or proxy card provided, and no
additional action is required to be taken by stockholders who have
already submitted their proxy. Stockholders that would like to vote
at the Annual Meeting (instead of by proxy) should contact the
Company’s Voting Inspector in advance of the meeting at (207)
878-2770 Ext. 0 or via email at: mail@immucell.com to arrange to
vote during the meeting.
Investors are encouraged to review the Company’s Form 10-Q for
the three-month period ended March 31, 2024 that was filed with the
SEC on Tuesday, May 14, 2024 and its updated Corporate Presentation
slide deck that provides an overview of the Company’s business and
is available under the “Investors” tab of the Company’s website at
www.immucell.com, or by request to the Company. For more
information about the Annual Meeting, including the matters to be
voted on during the Annual Meeting, please see the Company’s Notice
of Annual Meeting of Stockholders and its Proxy Statement, which
are available, along with the 2023 Annual Report on Form 10-K, at
www.immucell.com.
About ImmuCell:ImmuCell Corporation's
(Nasdaq: ICCC) purpose is to create scientifically
proven and practical products that improve the health and
productivity of dairy and beef cattle. ImmuCell manufactures and
markets First Defense®, providing
Immediate Immunity™ to newborn dairy and beef
calves, and is in the late stages of developing
Re-Tain®, a novel treatment for subclinical
mastitis in dairy cows without an FDA-required milk discard or meat
withhold that provides an alternative to traditional antibiotics.
Press releases and other information about the Company are
available at: http://www.immucell.com.
Contacts: |
Michael F.
Brigham, President and CEO |
|
ImmuCell Corporation |
|
(207) 878-2770 |
|
|
|
|
|
Joe Diaz, Robert Blum and Joe Dorame |
|
Lytham Partners, LLC |
|
(602) 889-9700 |
|
iccc@lythampartners.com |
ImmuCell (NASDAQ:ICCC)
Historical Stock Chart
From Aug 2024 to Sep 2024
ImmuCell (NASDAQ:ICCC)
Historical Stock Chart
From Sep 2023 to Sep 2024